Welcome!

News Feed Item

New HIV Treatment Launched by ViiV Healthcare Addresses Multiple Evolving Needs of People Living With HIV in the UK

LONDON, February 3, 2014 /PRNewswire/ --

ViiV Healthcare today launches its first new treatment, the integrase inhibitor, dolutegravir (TIVICAY®) a treatment for human immunodeficiency virus (HIV). It represents a new option for a wide range of people living with HIV, with proven efficacy in people starting treatment and in those who have developed resistance to multiple HIV drugs. Dolutegravir is indicated for use in combination with other antiretroviral agents for the treatment of adults and adolescents over 12 years of age infected with HIV. Most patients prescribed dolutegravir can take it as a convenient once-daily dose; it can be taken with or without food.[1]

Dr Anton Pozniak, HIV Service Director at Chelsea and Westminster Hospital commented, "Every day we face treatment choices in the management of HIV to balance efficacy with tolerability and convenience. As a new treatment alternative, dolutegravir provides us with an option that seems to address these issues and offers a positive treatment choice for both patients and physicians."

The dolutegravir clinical development programme involved more than 2,500 people living with HIV. The trials demonstrated the efficacy of dolutegravir in people at different stages of treatment, including those starting for the first time[2],[3],[4]as well as people who had started treatment and had developed resistance to other HIV medicines.[5],[6]

In people living with HIV and taking treatment for the first time, dolutegravir was shown to be:

  • comparable to another integrase inhibitor, raltegravir.[4]
  • superior to two other commonly prescribed HIV medicines: boosted darunavir and Atripla®.[2],[3]

In people who had been treated with other HIV medicines (not including integrase inhibitors) and had developed resistance, dolutegravir was found to be superior to raltegravir.[5]

For those who had developed resistance to other integrase inhibitors, dolutegravir was highly effective and reduced the amount of virus circulating in the blood to undetectable levels in more than half of people.[6]

Dolutegravir is generally well tolerated; in the clinical trials, fewer people stopped taking dolutegravir because of adverse reactions than those taking the comparator drugs. The most commonly seen side effects were nausea (seen in 15% of people taking dolutegravir), diarrhoea (16%) and headaches (14%).[1]

Dr Andrew Benzie, ViiV Healthcare UK Medical Director, commented, "The launch of dolutegravir is an important step forward in the treatment of people living with HIV in the UK. At ViiV Healthcare, our focus is on delivering advances in treatment and care for people living with HIV and dolutegravir is the first from our pipeline to be approved. We are working with the NHS to ensure that appropriate patients are able to access this treatment as soon as possible."

A recent UK survey conducted by IPSOS Mori* asking people living with HIV and clinicians about their feelings towards treatment showed that treatment effectiveness is the most important attribute for both groups, followed by side effects and then how easy the treatment is to take.

REFERENCES

  1. Tivicay (dolutegravir) Summary of Product Characteristics (SmPC). Available at http://www.viivhealthcare.com/our-medicines.aspx.
  2. Walmsley S, Antela A, Clumeck N et al. N Engl J Med 2013;369:1807-18.
  3. Clotet B et al. European AIDS Clinical Society (EACS), Brussels, 17 October 2013.
  4. Raffi F, Rachlis A, Stellbrink H-J et al. Lancet 2013;381(9868):735-743.
  5. Cahn P, Pozniak AL, Mingrone H et al Lancet 2013;382(9893):700-708.
  6. Nichols G, Lazzarin A, Maggiolo F, et al, on behalf of the VIKING-3 investigators. Poster presented at: 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; June 30-July 3, 2013. Kuala Lumpur, Malaysia. Poster TULBPE19

Notes to editors:

About Tivicay®(dolutegravir)

Tivicay® is the first new treatment delivered by ViiV Healthcare. It was approved by the U.S. FDA in August 2013 and by Health Canada in October 2013. It is a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor. Integrase inhibitors block HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells). This step is essential in the HIV replication cycle. Please refer to the full Summary of Product Characteristics for full prescribing information, including contraindications, special warnings and precautions for use.

Regulatory applications are being evaluated in other countries worldwide. Regulatory applications for ViiV Healthcare's developmental single-tablet regimen (STR) combining Tivicay with Kivexa®/Epzicom® (abacavir/lamivudine) were submitted to regulatory authorities in Europe, Canada and the U.S. in October 2013.

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. Shionogi joined as a 10% shareholder in October 2012. The company's aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit http://www.viivhealthcare.com.

* About the UK survey

Ipsos MORI interviewed a self-selected sample of 50 physicians and 50 nurses who treat patients with HIV and 50 adults aged 18 years and above diagnosed with HIV across Great Britain. Interviews were conducted online between 4th November and 18th December 2013. Respondents were drawn from healthcare specific market research panels. Data are unweighted and due to the small sample sizes, can only be considered as indicative rather than representative of the population.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Outscale, a global pure play Infrastructure as a Service provider and strategic partner of Dassault Systèmes, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2010, Outscale simplifies infrastructure complexities and boosts the business agility of its customers. Outscale delivers a secure, reliable and industrial strength solution for its customers, which in...
Most DevOps journeys involve several phases of maturity. Research shows that the inflection point where organizations begin to see maximum value is when they implement tight integration deploying their code to their infrastructure. Success at this level is the last barrier to at-will deployment. Storage, for instance, is more capable than where we read and write data. In his session at @DevOpsSummit at 20th Cloud Expo, Josh Atwell, a Developer Advocate for NetApp, will discuss the role and value...
SYS-CON Events announced today that Cloud Academy will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Cloud Academy is the industry’s most innovative, vendor-neutral cloud technology training platform. Cloud Academy provides continuous learning solutions for individuals and enterprise teams for Amazon Web Services, Microsoft Azure, Google Cloud Platform, and the most popular cloud computing technologies. Ge...
When NSA's digital armory was leaked, it was only a matter of time before the code was morphed into a ransom seeking worm. This talk, designed for C-level attendees, demonstrates a Live Hack of a virtual environment to show the ease in which any average user can leverage these tools and infiltrate their network environment. This session will include an overview of the Shadbrokers NSA leak situation.
As cloud adoption continues to transform business, today's global enterprises are challenged with managing a growing amount of information living outside of the data center. The rapid adoption of IoT and increasingly mobile workforce are exacerbating the problem. Ensuring secure data sharing and efficient backup poses capacity and bandwidth considerations as well as policy and regulatory compliance issues.
SYS-CON Events announced today that Interoute has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Interoute is the owner operator of Europe's largest network and a global cloud services platform, which encompasses over 70,000 km of lit fiber, 15 data centers, 17 virtual data centers and 33 colocation centers, with connections to 195 additional partner data centers. Our full-service Unifie...
SYS-CON Events announced today that delaPlex will exhibit at SYS-CON's @ThingsExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. delaPlex pioneered Software Development as a Service (SDaaS), which provides scalable resources to build, test, and deploy software. It’s a fast and more reliable way to develop a new product or expand your in-house team.
In his opening keynote at 20th Cloud Expo, Michael Maximilien, Research Scientist, Architect, and Engineer at IBM, will motivate why realizing the full potential of the cloud and social data requires artificial intelligence. By mixing Cloud Foundry and the rich set of Watson services, IBM's Bluemix is the best cloud operating system for enterprises today, providing rapid development and deployment of applications that can take advantage of the rich catalog of Watson services to help drive insigh...
Amazon started as an online bookseller 20 years ago. Since then, it has evolved into a technology juggernaut that has disrupted multiple markets and industries and touches many aspects of our lives. It is a relentless technology and business model innovator driving disruption throughout numerous ecosystems. Amazon’s AWS revenues alone are approaching $16B a year making it one of the largest IT companies in the world. With dominant offerings in Cloud, IoT, eCommerce, Big Data, AI, Digital Assis...
The 21st International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @ThingsExpo Silicon Valley Call for Papers is now open.
For financial firms, the cloud is going to increasingly become a crucial part of dealing with customers over the next five years and beyond, particularly with the growing use and acceptance of virtual currencies. There are new data storage paradigms on the horizon that will deliver secure solutions for storing and moving sensitive financial data around the world without touching terrestrial networks. In his session at 20th Cloud Expo, Cliff Beek, President of Cloud Constellation Corporation, w...
Interested in leveling up on your Cloud Foundry skills? Join IBM for Cloud Foundry Days on June 7 at Cloud Expo New York at the Javits Center in New York City. Cloud Foundry Days is a free half day educational conference and networking event. Come find out why Cloud Foundry is the industry's fastest-growing and most adopted cloud application platform.
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
As enterprise cloud becomes the norm, businesses and government programs must address compounded regulatory compliance related to data privacy and information protection. The most recent, Controlled Unclassified Information and the EU’s GDPR have board level implications and companies still struggle with demonstrating due diligence. Developers and DevOps leaders, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by in...